Summary
Intuitive Surgical, Inc. (ISRG) demonstrated a resilient business model in its 2014 10-K filing, despite a year-over-year revenue decrease to $2.1 billion. This decline was primarily driven by a significant drop in da Vinci Surgical System unit shipments, down 24% to 431 units. However, the company saw growth in recurring revenue streams, with instruments and accessories revenue increasing by 4% to $1.1 billion and service revenue rising by 8% to $429 million. Recurring revenue now constitutes 70% of total revenue, highlighting the growing importance of consumables and services in ISRG's business. The company also faced challenges including a 36% decrease in operating income, impacted by a substantial product liability charge of $82.4 million and ongoing litigation. Despite these headwinds, ISRG continued to invest in research and development ($178 million), reflecting its commitment to innovation, including the launch of the new da Vinci Xi Surgical System. The company maintained a strong cash position with $2.5 billion in cash, cash equivalents, and investments at year-end, supporting its ongoing operations and strategic initiatives.
Financial Highlights
48 data points| Revenue | $2.13B |
| Cost of Revenue | $717.90M |
| Gross Profit | $1.41B |
| R&D Expenses | $178.00M |
| SG&A Expenses | $691.00M |
| Operating Expenses | $869.00M |
| Operating Income | $544.80M |
| Net Income | $418.80M |
| EPS (Basic) | $1.26 |
| EPS (Diluted) | $1.23 |
| Shares Outstanding (Basic) | 332.10M |
| Shares Outstanding (Diluted) | 339.30M |
Key Highlights
- 1Total revenue declined by 6% to $2.13 billion in 2014, primarily due to a 24% decrease in system revenue, driven by lower unit shipments (431 units) compared to 2013 (546 units).
- 2Recurring revenue, comprising instruments, accessories, and service, grew by 5% to $1.5 billion, representing 70% of total revenue, indicating a growing reliance on these higher-margin segments.
- 3Procedure volume increased by approximately 9% to 570,000 in 2014, driven by growth in general surgery in the U.S. and worldwide urologic procedures.
- 4Operating income saw a significant decrease of 36% to $544.8 million, largely due to an $82.4 million pre-tax charge for product liability claim settlements and increased legal costs.
- 5The company launched its fourth-generation da Vinci Xi Surgical System in the U.S. in April 2014, aiming to enhance surgical capabilities and expand its product offerings.
- 6Intuitive Surgical ended 2014 with a strong liquidity position, holding $2.5 billion in cash, cash equivalents, and investments, though this was a decrease from $2.8 billion in 2013 due to share repurchases and capital expenditures.
- 7Product liability litigation remained a significant concern, with the company recording substantial charges and facing ongoing claims, though it maintained its belief in the safety and efficacy of its products.